Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1

Abstract excerpt

Neurofibromatosis type 1 (NF1) results from germline mutations in the tumor-suppressor gene NF1 and predisposes patients to developing nervous system tumors. Twenty percent of NF1 patients harbor nonsense mutations resulting in premature termination codons (PTCs). Nonsense suppression therapies can facilitate ribosomal readthrough of PTCs to restore full-length protein, but their potential in NF1 is...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Neuroblastoma Research and Treatments
• Share to Neuroendocrine Tumor Research Advances
• Share to Neurofibromatosis and Schwannoma Cases